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Summary This study was designed to compare the effects of alfentanil and
midazolam pre-medication on patient comfort during and after flexible broncho-
scopy.
A randomised, double-blind study was performed; 40 patients received alfentanil
and 29 midazolam. Subjects completed questionnaires about discomfort and adverse
effects immediately post-procedure and 24 h later. The bronchoscopist also
completed a questionnaire.
No difference in patient discomfort was found immediately post-procedure and no
differences were found for amount of topical lignocaine used or minimum oxygen
saturation. Operators reported no overall difference between the agents for ease of
procedure but about 20% less cough was reported in the alfentanil group (P ¼ 0:02).
Patient discomfort scores in the 24 h questionnaire were significantly lower in
patients given midazolam (P ¼ 0:01 for nasal discomfort, P ¼ 0:003 for throat
discomfort) but drowsiness was commoner in this group (P ¼ 0:04). There was no
significant difference in patients’ reports of cough, nausea or vomiting or their
willingness to have a repeat procedure.
In conclusion, cough during bronchoscopy was slightly less marked with alfentanil
than midazolam pre-medication but this made no difference to the ease of
procedure or to overall patient discomfort. Patients given midazolam reported less
discomfort when asked about the test 24 h later.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
The British Thoracic Society guidelines on diagnos-
tic flexible bronchoscopy (FB) stated that sedation
was not a pre-requisite but was of benefit in
anxious patients or those requesting it.1 A number
of studies have shown that doctors underestimate
the discomfort felt by patients undergoing FB.2–4 In
one study, 81% of patients stated that they would
prefer sedation.4 Common agents for sedation are
benzodiazepines which have anxiolytic and amnesic
effects and opiates which have an analgesic effect
and may decrease cough.
Currently, we use one of two short acting agents
for pre-medication, namely a benzodiazepine
(midazolam) or an opiate (alfentanil). In the only
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published study comparing these two agents, there
was a significant decrease in cough in the patients
who received alfentanil but no difference in the
discomfort reported by the patient or observed by
the operator.5 We undertook this study to deter-
mine if there was any difference between these
agents in terms of patient discomfort. We also
studied ease of procedure for the bronchoscopist
and safety as judged by level of desaturation and
amount of topical anaesthesia. In addition, patients
were asked to report symptoms 24 h post-procedure
to evaluate the side effects of the medications and
to assess if the amnesic effect of midazolam led to
more favourable recall of the procedure.
Methods
Patients requiring FB at a university hospital were
informed that there was uncertainty about the
optimal pre-medication for this procedure and they
were given a leaflet describing the trial protocol.
Sixty-nine patients agreed to enter the study and
written informed consent was obtained. Approval
for the study was gained from the local research
ethics committee. Subjects were randomised by an
unblinded physician who opened a sealed opaque
envelope containing an instruction to give alfenta-
nil or midazolam pre-medication. 10 of each type
of envelope were prepared and shuffled into
random order. Envelopes were picked out then
put back and shuffled for reuse. The patient and
operator were blinded to the sedative agent.
Sedation was administered by the unblinded phy-
sician who was present throughout the broncho-
scopy procedure. This doctor gave a starting dose
of 0.5–1mg of alfentanil or 2.5–5mg of midazolam
intravenously. Incremental doses were given as
needed to optimise patient comfort on the instruc-
tion of the operator who remained unaware of
which agent was being administered. The 4
physicians involved in the study alternated as
operators or unblinded observers over the period
of the study. All operators were experienced
bronchoscopists. All patients received topical lig-
nocaine gel to the nose prior to insertion of the
scope. During the procedure there was continuous
monitoring of oxygen saturation by pulse oximetry
and the minimum value reached was noted. The
amount of topical 2% lignocaine applied to the
vocal cords and bronchial tree was recorded by the
operator. Patients were asked to score discomfort
in the nose, throat and lungs on a 7 point modified
Likert scale as follows: 1¼ no discomfort, 2¼ very
mild, 3¼mild, 4¼moderate, 5¼ quite severe,
6¼ very severe, 7¼worst possible discomfort. This
score had detected significant differences in
patient discomfort in a previous (unpublished)
audit on our unit of 125 patients comparing those
receiving midazolam for bronchoscopy with those
who chose to have no sedation (mean score with
midazolam 2.0 V 2.8 with no sedation, Mann-
Whitney; P ¼ 0:0001).
The operator was asked to score apparent patient
discomfort on the same scale as the patient and the
ease of the procedure was recorded on a 6-point
scale ranging from ‘‘very easy’’ to ‘‘not possible due
to patient discomfort’’. The patient’s level of cough
was documented by the operator on a 5-point scale
ranging from ‘‘none’’ to ‘‘very severe’’. Patients
were also given a questionnaire in a stamped-
addressed envelope to complete at home 24h after
the procedure. If they were hospital in-patients, the
questionnaire was given to them on the ward. This
questionnaire contained the same discomfort score
for the nose, throat and lungs (see above), regard-
ing the procedure, and also asked patients about 6
specific symptoms during the 24 h post-procedure;
drowsiness, cough, soreness in the nose, soreness in
the throat, feeling sick and vomiting. Subjects were
asked to rate these symptoms as none, mild,
moderate or severe. Willingness to have the
procedure again was assessed with 4 choices, yes
without hesitation, yes reluctantly, probably not or
definitely not. Patients were asked about prefer-
ence for type of sedation if a repeat procedure was
necessary with the options of no sedation, light
sedation or heavy sedation.
Results were analysed with the statistics package
Prism version 3.0 (GraphPad Software, San Diego,
USA). Mann-Whitney tests performed except where
specified.
Results
Sixty nine patients entered the study of whom 40
(58%) were randomised to receive alfentanil and 29
(42%) to midazolam. This uneven recruitment was a
non-significant chance occurrence within the ran-
domisation process (Fisher’s exact test; P ¼ 0:09).
All patients completed the first questionnaire
immediately after the procedure and 46 patients
(67%) returned the second questionnaire 24 h after
the procedure of whom 30 (64%) had received
alfentanil and 16 (35%) midazolam. It was not
possible to send reminders to patients who failed
to return questionnaires because the responses
might have been completed more than 24 h post-
procedure.
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Operator reports were not completed for 3
subjects of whom 2 had received alfentanil and 1
had received midazolam. In these 3 cases, the
operator accidentally became aware of which
agent had been given prior to completing the
operator scoring sheet. The patients remained
blind to what treatment had been given and
continued in the study. The mean dose of alfentanil
was 0.95mg (range 0.5–2mg) and the mean dose of
midazolam was 4.2mg (range 2.5–8mg). All pa-
tients had bronchoscopy via the nose apart from
one by mouth in the alfentanil group. There was no
difference in patient safety in terms of mean
minimum oxygen saturation (91.2% with alfentanil
and 90.8% with midazolam, P ¼ 0:4376) and mean
amount of topical 2% lignocaine used (18.6mls
with alfentanil and 18.5mls with midazolam,
P ¼ 0:9537). There was no significant difference in
patient scores of discomfort for FB immediately
post-procedure but reporting of the procedure at
24 h showed that discomfort scores were signifi-
cantly less in the nose and throat (but not in the
lungs) in patients who had received midazolam
(Fig. 1). There was no significant difference in
operator reporting of ease of procedure or operator
scoring of patient tolerance of the procedure
between agents (Table 1). A small but significant
difference in operator reporting of cough was found
in favour of alfentanil (P ¼ 0:02). The operator
reported no cough in 29% of patients who received
alfentanil compared with 7% of those who received
midazolam. Moderate cough was also less common
with alfentanil (19%) than with midazolam (39%)
(Fig. 2).
Bronchoscopic procedures were not significantly
different between the two groups. Most patients
had one of, or a combination of, a wash, brush or
endobronchial biopsy. 32.5% had an endobronchial
biopsy in the alfentanil group and 24% in the
midazolam group. One subject in each group had a
bronchoalveolar lavage and no patient had a
transbronchial biopsy.
During the 24 h post-procedure, there was no
significant difference in adverse symptoms be-
tween the 2 groups apart from drowsiness, which
was increased in the midazolam group (P ¼ 0:04;
Fishers exact test). Midazolam produced a more
favourable but non-significant (P ¼ 0:65; Fishers
exact test) response to the question of a repeat
procedure. 99% of patients who received midazo-
lam were willing for a repeat procedure compared
to 86% with alfentanil. All patients reported that
they would want sedation if a repeat procedure
were needed (patients who requested broncho-
scopy without sedation were not recruited into the
study). There was no difference between the
agents in response to type of sedation requested,
the majority (80% in the alfentanil group and 69% in
the midazolam group P ¼ 0:455; Fishers exact test),
expressing preference for light rather than heavy
sedation (Table 2).
Discussion
Most patients undergoing bronchoscopy (81% in a
study by Poi et al.4), would prefer to have sedation
because of anxiety, or fear of pain or discomfort.
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Figure 1 Median patient discomfort scores from ques-
tionnaires administered immediately post-procedure and
24 h post-procedure. Clear bars shows score for Alfenta-
nil, Black bars shows score for Midazolam. 1¼ no
discomfort, 7¼worst possible discomfort. Level of
significance by Mann-Whitney Test. *P ¼ 0:01; **P ¼ 0:003:
Table 1 Operator reports immediately post-bronchoscopy.
Operator reports Alfentanil Midazolam P-value (Mann-Whitney test)
Cough scale 1–5 2.0 (1–3) 2.5 (2–3) 0.02
Apparent patient discomfort scale 1–7 2.0 (2–4) 3.0 (2–4) 0.22
Ease of procedure scale 1–6 3.0 (2–3) 3.0 (2–3) 0.26
All values are medians with 25–75% confidence intervals.
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High anxiety scores pre-procedure have been
shown to lead to decreased tolerance of broncho-
scopy.6 A number of studies have shown that
bronchoscopists underestimate the discomfort felt
by the patient.2,6,7 In a study of UK chest
physicians, 89% reported that they give sedation
routinely.8 In this survey physicians reported the
use of a benzodiazepine (63%), an opiate (14%) or a
combination of opiate and benzodiazepine (12%).
Both medicines have properties that would be
expected to improve patient comfort namely
anxiolytic and amnesic effects with benzodiaze-
pines and anti-tussive and analgesic effects with
opiates. There has only been one previous study
comparing midazolam with alfentanil for bronco-
scopy. It is known that pre-medication with a
benzodiazepine compared to placebo makes the
procedure more tolerable and patients are more
willing to undergo a repeat test.6,7 One of these
studies7 showed that these findings were more
pronounced at 24 h illustrating the amnesic proper-
ties of benzodiazepines. Studies with intermediate
acting opiates have not shown much benefit for
patient tolerance compared to placebo.2,9
There have been no studies comparing the short
acting intravenous opiate alfentanil with placebo.
Alfentanil has been compared with the longer
acting intramuscular opiate papaveratum combined
with intravenous diazepam and significantly less
cough was recorded with alfentanil but there were
no difference in patient discomfort.10
The present study had a number of limitations.
The sample size was relatively small and there was
a statistically non-significant difference in group
sizes resulting from uneven randomisation. Only 46
of 69 patients (66%) returned a questionnaire 24 h
post-procedure with more returned from the
alfentanil group (75% versus 55%). Drowsiness and
amnesia may have contributed to the lower rate of
return in the midazolam group. Most of the patients
were day cases and many forgot to send the
questionnaire back to the hospital despite being
given a stamped addressed envelope. However, we
were able to detect statistically significant differ-
ences between the groups immediately post-pro-
cedure and at 24 h, confirming that the sample size
was sufficient to detect clinically important differ-
ences between the groups.
Our findings support those of Grieg et al. who
found a significant decrease in cough during
bronchoscopy amongst patients given alfentanil
but this made no difference to overall patient
discomfort.5 Unlike them we did not find a
decrease in topical lignocaine use associated with
the reduced coughing. We had postulated that a
decrease in cough might make the procedure easier
for the bronchoscopist, a question that has not
previously been addressed. There was however no
difference found between the two agents with
regard to the ease of the procedure as scored by
the operator. The amnesic properties of midazolam
only become apparent in the second questionnaire,
24 h post-bronchoscopy, when a significant de-
crease in nasal and throat discomfort scores for
the procedure was reported compared to the
alfentanil group. If the unreturned questionnaires
belonged to the drowsiest patients, the level of
drowsiness (and amnesia for discomfort) in the
midazolam group may have been even greater than
we have reported.
The 24 h questionnaire also assessed post-proce-
dure symptoms, to our knowledge this is the first
report of specific delayed adverse effects in
relation to type of sedation received. One previous
study has asked about specific symptoms pre- and
48 h post-bronchoscopy11 and found a significant
increase in nose pain, throat pain, and swallowing
pain after sedation with either midazolam or
alfentanil.
Mild nose discomfort was reported by a substan-
tial number of patients in the 24 h questionnaire.
Soreness in the throat post-bronchoscopy was
common with no difference between agents. Gomm
et al. found a similar incidence in their study of 100
patients, 58% reported a sore throat post-FB.3
Patients should be advised that they may experi-
ence discomfort in the upper respiratory tract after
a bronchoscopy and should be encouraged to take
pain relief as needed. Drowsiness post-procedure
was unsurprisingly more common in patients re-
ceiving midazolam. This drowsiness was usually
mild (56%) although 19% of patients recorded it as
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Figure 2 Cough scores reported by operators, 0 indicates
scores for patients given alfentanil,  indicates scores
for patients given midazolam. Key to scores: 1¼No
cough, 2¼ Slight cough, 3¼Moderate cough, 4¼ Severe
cough, 5¼Very severe cough.
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severe. An interesting finding was that 39% of
patients in the alfentanil group reported moderate
or severe drowsiness in the 24 h post-bronchoscopy.
We found no difference between the two agents
in nausea post-procedure with about 20% in each
group reporting it as mild and about 10% as
moderate or severe. The incidence of vomiting
was similar between the two groups although
unexpectedly 2 of the patients (13%) in the
midazolam group reported severe vomiting. It
may be that patients misclassified an expectoration
of bronchial secretions post-procedure as vomiting
as this symptom is not reported to be common in
most previous studies of bronchoscopy. However,
one other study has found a similar rate of self-
reported vomiting (18%), post-flexible broncho-
scopy so ours is not an isolated finding.3
Combination therapy with alfentanil and midazo-
lam is used in some centres but there has only been
one study looking at these two agents and of
concern was the trend to desaturate more with
combined therapy.5 Alfentanil and midazolam in
combination were advocated in a review of sedation
for bronchoscopy, the authors stated the combina-
tion of these 2 agents in their practice provided
excellent operating conditions and was safe.12
However, it would seem prudent to await further
studies on combination of the agents before making
such a recommendation in view of the tendency for
greater desaturation if two or more drugs are given.
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Table 2 Symptoms during the 24 h post-bronchoscopy.
Patient reports Alfentanil Midazolam P-value (Fishers
exact test)
Cough
None 15% of subjects 40% of subjects 0.13
Mild 44% 27%
Moderate 30% 27%
Severe 11% 6%
Soreness in nose
None 75% of subjects 56% 0.31
Mild 21% 38%
Moderate 4% 6%
Severe 0 0
Soreness in throat
None 43% of subjects 50% 0.76
Mild 32% 31%
Moderate 25% 19%
Severe 0 0
Nausea post-procedure
None 68% of subjects 69% 1.0
Mild 18% 19%
Moderate 11% 6%
Severe 3% 6%
Drowsiness
None 29% of subjects 0 0.04
Mild 32% 56%
Moderate 36% 25%
Severe 3% 19%
Vomiting
None 92% of subjects 81% 0.54
Mild 4% 6%
Moderate 4% 0
Severe 0 13%
Would you have a repeat
procedure?
86% of subjects replied
‘‘Yes’’
99% of subjects replied
‘‘Yes’’
0.65
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In conclusion our study is in agreement with
previous studies which have shown that alfentanil
decreases cough during FB but this has no effect on
overall patient discomfort or ease of procedure for
the operator. Patients who received midazolam
reported significantly less procedure-related dis-
comfort at 24 h. Discomfort in the nose and throat
is common post-bronchoscopy and is not altered by
the type of pre-medication received.
This study suggests that there is no important
difference between midazolam and alfentanil with
respect to patient discomfort or safety on the day of
bronchoscopy but patients long-term recall of the
procedure is less unpleasant if midazolam is given.
The amnesic and anxiolytic properties of midazolam
may be more beneficial for patients than the anti-
tussive and analgesic properties of alfentanil.
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